Global Hepatitis B Vaccination Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hepatitis B Vaccination Market Insights, Forecast to 2034
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.
Global Hepatitis B Vaccination market is expected to reach to US$ 1079 million in 2024, with a positive growth of %, compared with US$ 1063 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Hepatitis B Vaccination industry is evaluated to reach US$ 1179.8 million in 2029. The CAGR will be 1.5% during 2024 to 2029.
The hepatitis B vaccination market is driven by the increasing focus on disease prevention and the rising awareness of the importance of immunization. Hepatitis B vaccines provide essential protection against the hepatitis B virus (HBV), which can cause chronic liver infections and increase the risk of liver cirrhosis and cancer. The rise in the prevalence of hepatitis B infections and the need for effective control of the disease contribute to market growth as vaccination plays a crucial role in reducing transmission and preventing complications. Moreover, advancements in vaccine technology, such as the development of combination vaccines and birth dose administration, have improved vaccine accessibility and coverage. However, the market also faces challenges, including vaccine supply limitations and the need for ongoing public health initiatives to address barriers to vaccination, such as vaccine hesitancy and lack of awareness. Additionally, ensuring equitable access to hepatitis B vaccines and increasing vaccination rates in high-risk populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable hepatitis B vaccines, collaborate with healthcare providers and governments to implement vaccination programs, and address the challenges to meet the increasing demand for effective and accessible protection against hepatitis B.
Report Covers
This report presents an overview of global Hepatitis B Vaccination market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Hepatitis B Vaccination market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute
Segment by Type
Yeast Derived
CHO Derived
Children
Adult
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Hepatitis B Vaccination plant distribution, commercial date of Hepatitis B Vaccination, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Hepatitis B Vaccination introduction, etc. Hepatitis B Vaccination Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Hepatitis B Vaccination
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Hepatitis B Vaccination market is expected to reach to US$ 1079 million in 2024, with a positive growth of %, compared with US$ 1063 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Hepatitis B Vaccination industry is evaluated to reach US$ 1179.8 million in 2029. The CAGR will be 1.5% during 2024 to 2029.
The hepatitis B vaccination market is driven by the increasing focus on disease prevention and the rising awareness of the importance of immunization. Hepatitis B vaccines provide essential protection against the hepatitis B virus (HBV), which can cause chronic liver infections and increase the risk of liver cirrhosis and cancer. The rise in the prevalence of hepatitis B infections and the need for effective control of the disease contribute to market growth as vaccination plays a crucial role in reducing transmission and preventing complications. Moreover, advancements in vaccine technology, such as the development of combination vaccines and birth dose administration, have improved vaccine accessibility and coverage. However, the market also faces challenges, including vaccine supply limitations and the need for ongoing public health initiatives to address barriers to vaccination, such as vaccine hesitancy and lack of awareness. Additionally, ensuring equitable access to hepatitis B vaccines and increasing vaccination rates in high-risk populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable hepatitis B vaccines, collaborate with healthcare providers and governments to implement vaccination programs, and address the challenges to meet the increasing demand for effective and accessible protection against hepatitis B.
Report Covers
This report presents an overview of global Hepatitis B Vaccination market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Hepatitis B Vaccination market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute
Segment by Type
Yeast Derived
CHO Derived
Segment by Application
Children
Adult
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Hepatitis B Vaccination plant distribution, commercial date of Hepatitis B Vaccination, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Hepatitis B Vaccination introduction, etc. Hepatitis B Vaccination Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Hepatitis B Vaccination
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices